GADOTERIDOL

Gadoteridol is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI). It enhances the quality of MRI scans by improving the visualization of abnormal tissues, blood vessels, and lesions. Gadoteridol is typically administered intravenously and is known for its safety and rapid elimination from the body through the kidneys.

Indications

Contrast enhancement in MRI for detecting and visualizing: - Central nervous system lesions (e.g., tumors, inflammation, multiple sclerosis) - Vascular abnormalities - Other pathologies requiring improved MRI imaging

Dosage

- Adults: Usually 0.1 mmol/kg body weight intravenously as a single injection, followed by a flush of normal saline. - Pediatric use: Dosage should be carefully adjusted based on weight and clinical condition. - Administration must be under supervision of a trained healthcare professional.

Contra-Indications

- Known hypersensitivity to gadolinium-based contrast agents or any component of Gadoteridol - Severe renal impairment (unless benefits outweigh risks)

Special Precautions

- Assess renal function before administration (risk of nephrogenic systemic fibrosis in patients with severe kidney disease) - Use caution in pregnant or breastfeeding women; risk vs. benefit should be considered - Monitor patients with history of allergic reactions to contrast agents

Side Effects

- Common: nausea, headache, dizziness, injection site reactions - Less common: taste alteration, rash, mild hypotension - Rare but serious: allergic reactions, nephrogenic systemic fibrosis (in patients with severe kidney dysfunction)

Drug Interactions

- No significant drug interactions have been reported, but caution with other nephrotoxic drugs is advised. - Avoid concurrent use with other gadolinium-based contrast agents within a short time frame.